meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced NSCLC - maintenance (M)
laNSCLC - M - all population
1
laNSCLC - M - EGFR mutant
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
versus all
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
durvalumab based treatment
durvalumab alone
laNSCLC - M - all population
1
Comparator:
vs placebo;
Risk of bias:
low;
some concerns;
high;
NA;